At press time, the Office of Inspector General issued its final compliance program guidance for pharmaceutical manufacturers, available at The guidance has major implications for CME providers. It underscores that commercial supporters must not have influence over content or faculty of CME. It also says ā€œcodes of conduct promulgated by the CME industry may provide a useful starting point for manufacturers when reviewing their CME arrangements.ā€ We will offer analysis and ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only unlock the OIG ISSUES FINAL PHARMA GUIDANCE, you'll also gain access to exclusive premium content.

Already registered? here.